A study to investigate the effect of iclaprim in patients with hospital acquired bacterial pneumonia

Trial Profile

A study to investigate the effect of iclaprim in patients with hospital acquired bacterial pneumonia

Planning
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2016

At a glance

  • Drugs Iclaprim (Primary)
  • Indications Nosocomial pneumonia
  • Focus Registrational; Therapeutic Use
  • Sponsors Motif Bio
  • Most Recent Events

    • 28 Jul 2015 New trial record
    • 15 Apr 2015 According to a Motif Bio media release, the FDA has agreed to the proposed phase III clinical development programme for iclaprim. The FDA confirmed that two ABSSSI trials or one ABSSSI trial plus one HABP trial meeting their pre-specified primary endpoints are required for approval of iclaprim.
    • 15 Apr 2015 According to a Motif Bio media release, this trial is expected to being in the second half of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top